{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:51:14Z","timestamp":1790200274950,"version":"4.1.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Children\u2019s Oncology Group (COG) trial AHOD0431 reduced systemic therapy and used response-adapted involved-field radiotherapy (IFRT) in early-stage pediatric classic Hodgkin lymphoma. We investigated the impact of positron emission tomographic response after 1 cycle (PET1) and on IFRT outcomes and pattern of relapse. Patients in AHOD0431 underwent PET1 response assessment after AVPC (doxorubicin, vincristine, prednisone, and cyclophosphamide). \u201cRapid early responders\u201d (RERs) had a negative PET1 (PET1\u2212); \u201cslow early responders\u201d (SERs) had a positive PET1 (PET1+). Patients with a partial response by computed tomographic and functional imaging after 3 chemotherapy cycles received 21-Gy IFRT, whereas complete responders had no IFRT. Progression-free survival (PFS) was evaluated for RERs and SERs treated with or without IFRT. Recurrence sites were initial, new, or both. Relapses involving initial sites were characterized as \u201cwithin the PET1+ site\u201d or \u201cinitially involved but outside the PET1+ site.\u201d Median follow-up was 118 months. The 10-year PFS rate among RERs was 96.6% with IFRT and 84.1% without IFRT (P = .10), whereas SERs were 80.9% with IFRT and 64.0% without IFRT (P = .03). Among 90 RERs who did not receive IFRT, all 14 relapses included an initial site. Among 45 SERs receiving no IFRT, 14 of 16 relapses were in the initial site (9 PET1+ site only). Among 58 patients receiving IFRT, 5 of 10 relapses were in the PET1+ site. After 3 cycles of AVPC alone, RERs showed favorable results. Conversely, SERs had unfavorable outcomes with AVPC alone, although they improved with 21-Gy IFRT. RT remains an important component of treatment for SERs. This trial was registered at www.clinicaltrials.gov\u00a0as #NCT00302003.<\/jats:p>","DOI":"10.1182\/blood.2022016098","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T19:03:35Z","timestamp":1656443015000},"page":"1086-1093","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1659-8337","authenticated-orcid":false,"given":"Akash","family":"Parekh","sequence":"first","affiliation":[{"name":"1Department of Radiation Oncology, University of Florida, Gainesville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Keller","sequence":"additional","affiliation":[{"name":"2Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta and Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"McCarten","sequence":"additional","affiliation":[{"name":"3Imaging and Radiation Oncology Core, Lincoln, RI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Kessel","sequence":"additional","affiliation":[{"name":"3Imaging and Radiation Oncology Core, Lincoln, RI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Cho","sequence":"additional","affiliation":[{"name":"4Nuclear Medicine Section, Department of Radiobiology, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Pei","sequence":"additional","affiliation":[{"name":"5Department of Biostatistics, University of Florida College of Public Health and Health Professions and College of Medicine, Gainesville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[{"name":"5Department of Biostatistics, University of Florida College of Public Health and Health Professions and College of Medicine, Gainesville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Castellino","sequence":"additional","affiliation":[{"name":"2Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta and Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis S.","family":"Constine","sequence":"additional","affiliation":[{"name":"6Departments of Radiation Oncology and Pediatrics, University of Rochester Medical Center, Rochester, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy L.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4687-4582","authenticated-orcid":false,"given":"David","family":"Hodgson","sequence":"additional","affiliation":[{"name":"8Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara M.","family":"Kelly","sequence":"additional","affiliation":[{"name":"9Department of Pediatrics, Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2312-5418","authenticated-orcid":false,"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"10Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2022090815230985900_B1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1001\/jamaoncol.2018.5911","article-title":"Association of combined modality therapy vs chemotherapy alone with overall survival in early-stage pediatric Hodgkin lymphoma","volume":"5","author":"Jhawar","year":"2019","journal-title":"JAMA Oncol."},{"issue":"6","key":"2022090815230985900_B2","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","article-title":"Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study","volume":"117","author":"Castellino","year":"2011","journal-title":"Blood."},{"issue":"7","key":"2022090815230985900_B3","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2009.24.8062","article-title":"Second malignant neoplasms in survivors of pediatric Hodgkin\u2019s lymphoma treated with low-dose radiation and chemotherapy","volume":"28","author":"O\u2019Brien","year":"2010","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022090815230985900_B4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2006.08.4772","article-title":"Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin\u2019s disease","volume":"25","author":"Donaldson","year":"2007","journal-title":"J Clin Oncol."},{"issue":"12","key":"2022090815230985900_B5","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.2012.45.3266","article-title":"Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95","volume":"31","author":"D\u00f6rffel","year":"2013","journal-title":"J Clin Oncol."},{"issue":"18","key":"2022090815230985900_B6","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1200\/JCO.2002.12.007","article-title":"Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin\u2019s disease who achieve a complete response to chemotherapy","volume":"20","author":"Nachman","year":"2002","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022090815230985900_B7","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2008-10-184143","article-title":"A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425","volume":"114","author":"Schwartz","year":"2009","journal-title":"Blood."},{"issue":"7","key":"2022090815230985900_B8","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/pbc.24279","article-title":"Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children\u2019s Oncology Group","volume":"59","author":"Tebbi","year":"2012","journal-title":"Pediatr Blood Cancer."},{"issue":"15","key":"2022090815230985900_B9","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1002\/cncr.31519","article-title":"Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: a report from the Children\u2019s Oncology Group","volume":"124","author":"Keller","year":"2018","journal-title":"Cancer."},{"issue":"32","key":"2022090815230985900_B10","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children\u2019s Oncology Group Study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol."},{"issue":"24","key":"2022090815230985900_B11","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/jama.2012.5847","article-title":"Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma","volume":"307","author":"Metzger","year":"2012","journal-title":"JAMA."},{"issue":"26","key":"2022090815230985900_B12","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1200\/JCO.2011.41.1819","article-title":"Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin\u2019s lymphoma \u2013 a report from the Children\u2019s Oncology Group","volume":"30","author":"Wolden","year":"2012","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022090815230985900_B13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2014.10.042","article-title":"Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children\u2019s Oncology Group","volume":"92","author":"Dharmarajan","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"33","key":"2022090815230985900_B14","doi-asserted-by":"crossref","first-page":"8406","DOI":"10.1200\/JCO.2004.00.8763","article-title":"Patterns of treatment failure in pediatric and young adult patients with Hodgkin\u2019s disease: local disease control with combined-modality therapy","volume":"23","author":"Krasin","year":"2005","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022090815230985900_B15","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/(SICI)1097-0142(19960915)78:6<1293::AID-CNCR18>3.0.CO;2-W","article-title":"Analysis of prognostic factors after the first relapse of Hodgkin\u2019s disease in 187 patients","volume":"78","author":"Brice","year":"1996","journal-title":"Cancer."},{"issue":"24","key":"2022090815230985900_B16","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol."},{"issue":"31","key":"2022090815230985900_B17","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol."},{"issue":"16","key":"2022090815230985900_B18","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol."},{"issue":"17","key":"2022090815230985900_B19","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med."},{"issue":"4","key":"2022090815230985900_B20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.14338\/IJPT-19-00077.1","article-title":"Irradiating residual disease to 30 Gy with proton therapy in pediatric mediastinal Hodgkin lymphoma","volume":"6","author":"Hoppe","year":"2020","journal-title":"Int J Part Ther."},{"issue":"1","key":"2022090815230985900_B21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","article-title":"Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial","volume":"23","author":"Mauz-K\u00f6rholz","year":"2022","journal-title":"Lancet Oncol."},{"issue":"2","key":"2022090815230985900_B22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijrobp.2021.07.1716","article-title":"Radiation therapy across pediatric Hodgkin lymphoma research group protocols: a report From the Staging, Evaluation, and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL) Group","volume":"112","author":"Hall","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"4","key":"2022090815230985900_B23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/MPH.0000000000001094","article-title":"ABVD without radiation for newly diagnosed pediatric and young adult patients with Hodgkin lymphoma: a single center retrospective analysis of 28 consecutive patients","volume":"40","author":"Stieglitz","year":"2018","journal-title":"J Pediatr Hematol Oncol."},{"issue":"6","key":"2022090815230985900_B24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.6004\/jnccn.2021.0027","article-title":"Pediatric Hodgkin lymphoma, version 3.2021","volume":"19","author":"Flerlage","year":"2021","journal-title":"J Natl Compr Canc Netw."},{"issue":"23","key":"2022090815230985900_B25","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","article-title":"Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin\u2019s lymphoma: the GPOH-HD-2002 study","volume":"28","author":"Mauz-K\u00f6rholz","year":"2010","journal-title":"J Clin Oncol."},{"key":"2022090815230985900_B26","first-page":"35","article-title":"First international inter-group study for classical Hodgkin lymphoma in children and adolescents: EuroNet-PHL-C1 report of the latest Interim Analysis [abstract]","volume":"101","author":"Landman-Parker","year":"2016","journal-title":"Haematologica."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/10\/1086\/1919017\/bloodbld2022016098.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/10\/1086\/1919017\/bloodbld2022016098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T15:25:05Z","timestamp":1662650705000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/10\/1086\/485708\/Targeted-radiotherapy-for-early-stage-low-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022016098","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]}}}